EGFR and neoplasm: Antibody and small-molecule inhibitors of EGFR were some of the first approved signaling pathway-targeted inhibitors (12, 13), and are used extensively in tumors bearing EGFR mutations or with EGFR overexpressed, as well as in other contexts in which EGFR signaling contributes to tumor growth and survival.